WO2007073552A1 - In vitro expansion of postpartum derived cells in roller bottles - Google Patents
In vitro expansion of postpartum derived cells in roller bottles Download PDFInfo
- Publication number
- WO2007073552A1 WO2007073552A1 PCT/US2006/062315 US2006062315W WO2007073552A1 WO 2007073552 A1 WO2007073552 A1 WO 2007073552A1 US 2006062315 W US2006062315 W US 2006062315W WO 2007073552 A1 WO2007073552 A1 WO 2007073552A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- days
- rpm
- rotational speed
- culture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
Definitions
- This relates generally to the growth and expansion of mammalian cells.
- this relates to methods for the in vitro growth and expansion of postpartum-derived cells in containers such as roller bottles.
- anchorage-dependent cells include many normal diploid cell strains, as well as most primary cell lines.
- Options for large-scale production of such cells include roller bottles, fiber beds and hollow fiber systems, multi-plate or stacked-plate culture systems, cell cubes, and microcarriers, each of which has advantages and disadvantages.
- Roller bottle-based methods of cell culture are probably the most commonly used method for growing anchorage-dependent and anchorage-preferred cells.
- Roller bottles are essentially cylindrical vessels, of glass or plastic, which are at least partially filled with a growth medium.
- Most modern roller bottles are made of a disposable plastic material.
- the bottles are placed on an apparatus that turns, causing the bottles to continuously "roll” or revolve at a typically constant speed of between about 5 and 250 revolutions per hour. The rolling motion allows the cells, which attach to the inside surfaces of the bottle, to bathe in the medium while having ample exchange of gases with the atmosphere in the bottles.
- Roller bottles are available in various sizes, each size providing a fixed amount of surface area and volume. Many bottles are available in the 1- 2 liter volume range. Two common sized commercial roller bottles provide 850 cm 2 and 1050cm 2 , respectively. For some applications, large size can be a limitation because roller bottles that are too large are difficult to handle where microbiological safety is critical. More recently roller bottles with expanded inner surfaces have become commercially available to help address the issue. Handling of roller bottle cultures, such as manipulations for subculture should be minimized where possible.
- Roller bottle-based culture systems provide many advantages including relatively low cost for equipment and set-up, relative ease of set-up, and ability to scale up or down according to needs.
- the bottles which are typically clear, allow for visual and microscopic inspection of the cells and the growth. Contaminated samples are easy to spot and can be discarded.
- the potential drawbacks include the relatively high level of skill required for seeding, transfers, harvest of cells or biologies produced, and other ongoing manipulation of the cells.
- the costs associated with ongoing operations may be high because of the skill level required.
- the risk of contamination is relatively high because of the amount of manipulation required.
- roller bottles are used still, even for the commercial production of some biologies.
- the attachment efficiency, as well as time to reach confluence the growth parameters of attached cells including maximum attainable density per unit surface area, detachment techniques, which arc required, and the efficiency of the detachment, scalability of the culture conditions, as well as homogeneity of the culture under scaled-up conditions, and the ability to successfully scale-up detachment procedures.
- Some of these considerations can be influenced by the inoculation parameters (such as rotational speed, media volume), culture conditions such as the rotational speed of the bottles, as well as the seeding density of the initial culture, the volume of medium used relative to the surface area and/or shape of the bottle, and the length of time the culture is incubated.
- the characteristics of the cells grown under scaled-up roller bottle conditions be those of the desired cell type in terms of surface markers, gene expression, viability (over 70 to 80%), and the like.
- the invention provides methods of maximizing the growth parameters of postpartum cells in roller bottle culture systems.
- methods of maximizing the number doublings of a culture of postpartum cells in a roller bottle culture system comprise using a rotational speed of at least about 0.85 rpm, using a media volume of at least about 100 ml in an 850 square centimeter culture bottle; using a seeding density of less than about 2500 cells per square centimeter; and incubating for at least about 5.5 days.
- Also in accordance with the present invention are methods of maximizing the rate of doubling of a culture of postpartum cells in a roller bottle culture system.
- the methods for maximizing the rate of doubling preferably comprise using a rotational speed of at least about 0.85 rpm, using about 300 ml of growth medium in an 850 square centimeter culture bottle; using a seeding density of less than about 2500 cells per square centimeter; and incubating for less than about 6 days.
- the invention provides methods of maximizing the density of cells at harvest for postpartum cells in a roller bottle culture system. These methods comprise using a rotational speed of about 0.5-1 rpm, using about 300 ml of growth medium in an 850 square centimeter culture bottle; using a seeding density of about 10,000 cells per square centimeter; and incubating for between about 5.5 to 6.7 days.
- Also provided in accordance with one aspect of the invention are methods of simultaneously maximizing doubling rate, harvest density, and the total number of population doublings for postpartum cells in a roller bottle culture system. These methods are also sometimes referred to herein as optimizing the roller bottle culture system for the foregoing parameters.
- the methods preferably comprise using a rotational speed of about 0.65-0.9 rpm, using at least about 300 ml of growth medium in an 850 square centimeter culture bottle; using a seeding density of less than about 2,500 cells per square centimeter; and incubating for between about 5.5 to 6.5 days.
- the foregoing methods are particularly useful where the postpartum cells are umbilicus-derived cells, and presently preferred postpartum cells are those which are substantially similar, or even identical to ATCC NOS PTA-6067 and PTA-6068.
- Figure 1 Calculated optimal rotational speed (1.0 rpni), media volume (112 ml), seeding density (2,500 cells/cm sq.), and days in culture (6.27 days) to achieve the maximal population doublings (3.04).
- the black line on each graph represents the plotted values of the factor levels (low to high along the x-axis) vs. population doublings (minimal to maximal along the y-axis).
- the blue line represents the single maximum y-axis value for all four graphs.
- the red line represents the point on the x-axis that the plotted value of the factors levels vs. population doublings value (black line) intersects the single maximum y-axis value (blue line) thus defining the optimal factor level.
- Figure 2 Calculated optimal rotational speed (0.92 rpm), media volume (300 ml), seeding density (2,500 cells/cm sq.), and days in culture (5 days) to achieve the minimal hours per population doubling (29.71).
- the black line on each graph represents the plotted values of the factor levels (low to high along the x-axis) vs. hours per population doublings (minimal to maximal along the y-axis).
- the blue line represents the single maximum y-axis value for all four graphs.
- the red line represents the point on the x-axis that the plotted value of the factors levels vs. hours per population doublings value (black line) intersects the single minimum y-axis value (blue line) thus defining the optimal factor level.
- Figure 3 Calculated optimal rotational speed (0.98 rpm), media volume (300 ml), seeding density (10,000 cells/cm sq.), and days in culture (6.67 days) to achieve the maximal harvest density (cell/cm sq.) (3.59E+04).
- the black line on each graph represents the plotted values of the factor levels (low to high along the x-axis) vs. maximal harvest density (minimal to maximal along the y-axis).
- the blue line represents the single maximum y-axis value for all four graphs.
- the red line represents the point on the x-axis that the plotted value of the factors levels vs. maximal harvest density (black line) intersects the single maximum y-axis value (blue line) thus defining the optimal factor level.
- Figure 4 Calculated optimal rotational speed (0.705 rpm), media volume (300 ml), seeding density (2,500 cells/cm sq.), and days in culture (6.1 days) to achieve the minimum hours/ population doubling (38.07 hours), maximum population doublings (3.17), and maximum harvest density (cell/ cm sq.)(l .8E+04).
- the black lines on each graph represent the plotted values of the factor levels (low to high along the x-axis) vs. response values (minimal to maximal along the y-axis).
- the blue line represents the single maximum, or minimal, y-axis value for all four graphs.
- the red line represents the point on the x-axis that the plotted value of the factors levels vs. response value (black line) intersects the single maximum y-axis value for population doublings and harvest density and the minimum y-axis value for hours per population doubling (blue line) thus defining the optimal factor levels.
- Figure 5 Population Doublings vs. Days in Culture of umbilical cell line 050604B expanded from passage six to passage nine under optimized roller bottle culture conditions
- the invention provides separate methods of maximizing the amount of anchorage-dependent cells available for harvest from a population of cells grown in a roller bottle culture system, the growth rate of such a culture, or the total number of doublings of such a culture.
- the invention also provides methods for simultaneously maximizing all three of the foregoing parameters. Cells and populations of cells produced by the foregoing methods are also provided herein
- roller bottle culture systems are known in the art of cell culture.
- roller bottle culture systems comprise at least a cell line of interest, growth medium, roller bottles, an apparatus for rotating the bottles, and means for harvesting the cells.
- the growth medium preferably comprises a basal medium, for example, Dulbecco's Modified Eagle's Medium (DMEM), Advanced DMEM, Ham's F12, or combinations thereof, for example 1 :1 DMEM:F12.
- DMEM Dulbecco's Modified Eagle's Medium
- the medium can be supplemented with serum, for example in some embodiments the medium is supplemented with fetal bovine serum (FBS) or new born calf scrum (NCS).
- FBS fetal bovine serum
- NCS new born calf scrum
- the scrum content can range in concentration from 0 (a scrum-frcc media) to 20% of the total volume of the medium.
- Growth factors for example, platelet derived growth factor BB (PDGF-BB), basic fibroblast growth factor (bFGF), and others, or combinations of such may be used to supplement the growth medium.
- PDGF-BB platelet derived growth factor BB
- bFGF basic fibroblast growth factor
- serum-containing or serum-free media can be with or without growth factor supplementation.
- Roller bottle culture systems typically further comprise means for controlling the temperature during the incubation, as well as means for aseptically handling the cultures, for example during initial seeding of the bottles with cells, or during subsequent transfers.
- Harvesting of the cells may be achieved through enzymatic treatment such as with trypsin, trypsin-EDTA, dispase, and collagenase, or other enzymes or combinations of enzymes with or without other components.
- Other commercial products such as but not limited to TrypLE Express (Gibco, Inc.) can utilized.
- the cells be also be harvested by manual operations including, for example, batch centrifugation, or harvesting can be automated.
- the methods of maximizing the amount of cells available for harvest preferably are applied to postpartum-derived cells, particularly cells derived from the placenta or umbilicus.
- Cells of the type preferred here are described in U.S. Patent Application Nos: 10/877,446 (placenta- derived cells) and 10/877,012 (umbilicus-derived cells), each filed June 25, 2004. The entireties of these applications are incorporated by reference herein.
- Also preferred are cells of the types available from the American type Culture Collection as ATCC Accession Nos. PTA-6067; PTA-6068; PTA-6074; PTA-6075; or PTA-6079, the characterization and description of each of which is also incorporated by reference herein.
- Particularly preferred for the present methods are directed to maximized or optimized methods for culturing umbilical- derived cells, for example, ATCC Accession Nos. PTA-6067 and PTA-6068.
- the invention provides methods of maximizing the number of population doublings achievable for a population of cells grown in a roller bottle culture system.
- the cells are postpartum-derived cells, and even more preferably the cells are umbilicus-derived cells.
- the cells are ATCC Accession No: PTA-6067 or PTA-6068.
- the independent variables which have been used to maximize the number of population doublings achievable in a roller bottle culture are rotational speed, seeding density of the cells into the bottles, time of incubation, and volume of medium placed in the bottle.
- rotational speed seeding density of the cells into the bottles
- time of incubation time of incubation
- volume of medium placed in the bottle volume of medium placed in the bottle.
- these independent variables have been tested, for reasons of practicality, within certain ranges. The skilled artisan will appreciate that other values outside of the tested ranges could be routinely tested using the same methodology, and these values may prove to offer incremental gains in the number of population doublings.
- Maximal response of the dependent variable, here the number of population doublings achieved is measured as a function of these parameters and embodiments not specifically exemplified herein are contemplated as part of this disclosure.
- RSM response surface methodology
- the bottles are filled about 100-300 ml of growth medium, in other embodiments about 100-200 ml are used, as can be seen from Figure 1. In one embodiment about 100-120 ml, or even 105-115 ml are placed in the bottles. In other embodiments, the bottles are filled with about 112 ml of growth medium to achieve maximal population doublings.
- the bottles are seeded with about 2500 to about 10,000 cells per square centimeter. In a preferred embodiment, the lower end of that range is used, for example seeding is with less than about 3000 cells per square centimeter.
- the seeding is at an even lower end of the tested range — the seeding is done with about 2500 cells per square centimeter.
- the seeding bottles are rotated during attachment and growth.
- the rotational speed is set at between about 0.5 to 1 rpm.
- the rotation is between about 0.75 and 1 rpm.
- the bottles are rotated at about 0.8 to 1 rpm. Rotation near or about 1 rpm is preferred as can be seen in Figure 1.
- the filled and seeded roller bottles are rotated and incubated for about 5 to 7 days to achieve maximal doublings.
- an incubation time of about 5.5 to about 6.5 days is preferred.
- incubation for about 6.2 to 6.3 days is also preferred.
- the independent variable can be selected as a set of parameters to maximize the number of population doublings.
- a roller bottle culture system that comprises a fill volume of about 112 ml of growth medium, and a seeding density of about 2500 cells per square centimeter, which is rotated at a speed of about 1 rpm for an incubation of about 6.2 days will provide the maximal population doublings achievable in such a system.
- roller bottles preferred for use are typically coated with an agent that aids in the attachment of the cells to the inner surface of the roller bottles, such as gelatin, extracellular matrix molecules (such as gelatin, laminin, vitronectin, f ⁇ bronectin, collagen types I, PV, and VI), or the like. While for many of the embodiments exemplified, a gelatin coating was used, other coating are deemed suitable and the skilled artisan will appreciate that commercially-available coated bottles are completely compatible with the methods taught herein. One example of such commercially available coated bottles are those coated with CellBind (available from Corning as catalog number 3907). The use of CellBind bottles and a comparison with gelatin-coated bottles is exemplified in Example 4 below. It is envisioned that various coating agents will be found acceptable for attachment and growth, of cells in accordance with the methods provided herein.
- an agent that aids in the attachment of the cells to the inner surface of the roller bottles such as gelatin, extracellular matrix molecules (such as gelatin, laminin, vitronect
- the invention provides methods of minimizing the number of hours/population doubling (see Figure 2), or alternatively expressed, maximizing the population doubling rate for a population of cells grown in a roller bottle culture system.
- the population doubling rate is the number of population doublings per unit time, and is a reciprocal of the hours per population doubling. Achieving maximal population doubling rate reduces the amount of time required to produce a needed number of cell for therapeutic applications and increases the total throughput of a culture system of limited capacity.
- the cells are postpartum-derived cells, and even more preferably the cells are umbilicus-derived cells. In a presently preferred embodiment the cells are ATCC Accession No: PTA-6067 or PTA-6068.
- roller bottles arc filled about 100- 300 ml of growth medium, preferably about 300 ml are used, as can be seen from Figure 2.
- the bottles are seeded with about 2500 to about 10,000 cells per square centimeter. In a presently preferred embodiment, the lower end of that range is used, for example seeding is with less than about 3000 cells per square centimeter. Still more preferred arc embodiments where the seeding is at about 2500 cells per square centimeter.
- the seeded bottles are rotated during attachment and growth.
- the rotational speed is set at between about 0.5 to 1 rpm, as can be seen from Figure 2.
- the rotation is between about 0.75 and 1 rpm. More preferably, the bottles are rotated at about 0.8 to 1 rpm. Rotation near or about 0.9 -1.0 rpm is presently preferred, as shown in the figure.
- the filled and seeded roller bottles are rotated and incubated for about 5 to 7 days, with an incubation time of about 5 to about 6 days preferred.
- Figure 2 shows that incubation for about 5 days is also preferred.
- the independent variables can be selected as a set of parameters to maximize the population doubling rate, based on the results shown in Figure 2.
- a roller bottle culture system that comprises a fill volume of about 300 ml of growth medium, and a seeding density of about 2500 cells per square centimeter, which is rotated at a speed of about 0.9 rpm for an incubation of about 5 days will provide the maximal population doubling rate achievable in such a system.
- the invention provides methods of maximizing the density of anchorage-dependent cells available for harvest from a population of cells grown in a roller bottle culture system.
- the cells are postpartum-derived cells, and even more preferably the cells are umbilicus-derived cells.
- the cells are ATCC Accession No: PTA-6067 or PTA-6068.
- the invention provides methods of maximizing the density of the cell population for harvest for a population of cells grown in a roller bottle culture system.
- Harvest density is expressed as the number of cells per square centimeter (of internal surface area in a roller bottle).
- roller bottles arc filled about 100-300 ml of growth medium, preferably about 300 ml are used, as can be seen from Figure 3.
- the bottles are seeded with about 2500 to about 10,000 cells per square centimeter, preferably the seeding density is selected from the lower end of that range, such as a value less than about 3000 cells per square centimeter. More preferred are those embodiments wherein seeding density is at about 2500 cells per square centimeter.
- the seeded bottles are rotated throughout attachment and growth at a speed between about 0.5 to 1 rpm, as shown in Figure 3.
- rotation is between about 0.75 and 1 rpm. More preferably, the bottles are rotated at about 0.8 to 1 rpm. Rotation near or about 0.9-1.0 rpm is presently preferred, for example 0.98 rpm, as shown in the figure.
- the filled and seeded roller bottles are rotated and incubated for about 5 to 7 days, with an incubation time of about 6 to about 7 days preferred.
- Figure 3 shows that incubation for about 5.8 to less than about 6 days or for about 6.5 to about 6.7 days is also preferred.
- the invention provides methods of simultaneously minimizing the number of hours/population doubling, while maximizing the number of population doublings and the harvest density (in cells per square centimeter) for a population of cells grown in a roller bottle culture system.
- Such optimization of the culture conditions makes the roller bottle culture system more useful for generating the number of cells required for a therapeutic application and increases the total throughput of a culture system of limited capacity.
- the cells are postpartum-derived cells, and even more preferably the cells are umbilicus-derived cells.
- the cells are ATCC Accession No: PTA-6067 or PTA-6068.
- the independent variables which have been adjusted to help simultaneously maximize the number of population doublings achievable, the rate of population doublings and the final harvest density of the cells in a roller bottle culture are the same as detailed above for maximizing the individual aspects: i.e. rotational speed, seeding density of the cells into the bottles, time of incubation, and volume of medium placed in the bottle. Maximal response of the dependent variables is measured and calculated as a function of these independent parameters.
- regression analysis and particularly RSM was utilized to help simultaneously maximize the three dependent variables as a function of the four independent variables.
- roller bottles are filled about 100-300 ml of growth medium, preferably about 300 ml are used, as can be seen with reference to Figure 4.
- the bottles arc seeded with about 2500 to about 10,000 cells per square centimeter.
- the lower end of that range is used, for example seeding is with less than about 3000 cells per square centimeter.
- the seeding is at about 2500 cells per square centimeter.
- Even lower seeding density is used is other embodiments.
- the seeded bottles are rotated during attachment and growth at speeds between about 0.5 to 1 rpm. With further reference to Figure 4, in can be seen that preferably, the rotation is between about 0.6 and 0.9 rpm.
- the bottles are rotated at about 0.65 to 0.93 rpm. Also preferred are culture systems wherein the rotation is near or about 0.85 - 0.9 rpm as can be seen in the figure.
- the filled and seeded roller bottles are rotated and incubated for about 5 to 7 days, with an incubation time of about 5.5 to about 6.5 days preferred.
- Figure 4 shows that incubation for about 6 days is also preferred, such as 5.9, 6.0, 6.1 or 6.2 days.
- the independent variables can be selected as a set of parameters to maximize the population doubling rate, based on the results shown in Figure 4.
- a roller bottle culture system that comprises a fill volume of about 300 ml of growth medium, and a seeding density of about 2500 cells per square centimeter, which is rotated at a speed of about 0.7 rpm for an incubation of about 6.1 days will provide the optimal population doubling rate, total number of doublings and harvest density for the cells achievable in such a system.
- the invention provides postpartum cells, preferably umibilicus-derived cells, that are produced are produced by any of the methods of the invention, for example the maximized methods or optimized.
- the cells are produced in populations for use as cell therapeutics, or to provide useful cellular product or byproducts, such as useful cellular factors, or proteins.
- cell therapeutic compositions comprising cells cultured by the methods provided herein.
- the cells that are cultured according to the methods provided are characterized as having substantially the same cell surface marker profile or gene expression profile as the starting cells.
- the cellular characteristics do not change when scaling up the culture conditions to increase quantities.
- the morphology, cell surface markers, and expression of hallmark genes that help distinguish or denote the therapeutic cell should remain substantially unchanged if not identical.
- the cells provided in accordance with the invention and the methods taught therein are substantially unchanged, or preferably identical in such characteristics as the same cells grown under laboratory conditions ad scale.
- the preferred umbilicus-derived cells retain substantially the same the cell surface marker profile of the cells from which they are grown.
- the cells produced according to the methods provided herein express more than one of surface markers for CDl O, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA- ABC. More preferably they express all of these markers.
- the cells also preferably do not express more than one of the cell surface markers for CD31, CD34, CD45, CDl 17, CD141, and HLA-DRDPDQ. More preferably the cells do not express any of the foregoing.
- the cells express an identical ceil surface marker profile with respect to each of CDlO, CD13, CD44, CD73, CD90, PDGFr-alpha, HLA-ABC, CD31, CD34, CD45, CDl 17, CD141, and HLA-DRDPDQ.
- preferred cells are positive for expression of CDlO, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-ABC, but negative for expression of CD31 5 CD34, CD45, CDl 17, CD141, and HLA-DRDPDQ.
- the skilled artisan will appreciate that are several ways to assess the cell surface marker profile of a cell line.
- a cell surface marker protein can be detected through use of a fluorescently-labeled antibody the cell is deemed positive and if the cell surface marker cannot be detected via fluorescent antibody, the cell is deemed negative for that marker.
- Table 6 provides a summary of the preferred cell surface markers for the umbilicus-derived cells of the invention.
- the cells produced in accordance with the methods of the invention preferably retain substantially the same, or even identical gene expression profile, particularly for genes whose expression help to characterize the cell, or serve as hallmarks indicative of that cell line.
- the umbilicus-derived cells of the invention are noted for the expression genes for reticulon, LDL-R, IL-8, and GAPDH.
- the cells provided are substantially similar, or even identical in various embodiments with respect to their expression of these genes.
- Cells The cells used were from umbilicus-derived cell line ATCC Accession Nos. PTA-6067 and/or PTA-6068.
- the growth medium used during the optimization experiments was Dulbccco's Modified Eagle Medium (DMEM) with low glucose, 15% Fetal Bovine Scrum, 1% Penicillin-Streptomycin, and 1 ppm 2-Mercaptoethanol.
- DMEM Dulbccco's Modified Eagle Medium
- Bottles 850 cm sq bottles were used (e.g. Corning catalog number 430851)
- Gelatin Coating Twenty (20) ml of 2% gelatin solution were added to each 850 cm sq bottle. The bottles were placed on the roller system for 20 minutes at 1 rpm. The excess gelatin solution was removed by aspiration and the bottles washed with 20 ml Phosphate Buffered Saline (PBS).
- PBS Phosphate Buffered Saline
- Table 1 Factors tested and the ran e of values tested.
- Table 2 Box-Behnken Response Surface Experimental Design to evaluate the factors and factor interactions that significantly effect cell yield as calculated by Minitab 14.0 statistical software.
- the highest and lowest factor levels for rotational speed (low 0.5 rpm, high 1.0 rpm).
- media volume (low 100ml, high 500ml), seeding density (low 2,500 cell/cm sq., high 10,000 cells/cm sq.) and days in culture (low 5 days, high 7days) are user-defined and the mid point is calculated.
- Table 3 Cells yield obtained from factor levels defined by Box-Behnken response surface experimental design. Harvest Density is expressed in cells/cm 2 .
- Table 5 Response Surface Regression Analysis: Hours/Doubling versus Rotational Speed, Media Volume, Seeding Density and Days in Culture.
- Table 6 Response Surface Regression Analysis: Population Doublings versus Rotational Speed, Media Volume, Seeding Density and Days in Culture.
- Seeding Density ( cells /cm, sq) 0.48500 0.07793 -6.223 00 ..000000
- Seeding Density (cells/cm sq) Media Volume (ml) *Days 0.17750 0.13498 -1.315 0 .213 Seeding Density (cells/cm sq) *Days 0.02000 0.13498 -0.148 0 .885
- Cells The cells used were umbilicus-derived cells identified as CBAT 050604B P6 (passage 6).
- Bottles The bottles used were 850 cm sq culture bottles (e.g. Corning catalog number 430851).
- Gelatin Coating Twenty milliliters of 2% gelatin solution were added to each 850 cm sq bottle. The bottles were placed on the roller system for 20 minutes. The gelatin solution was removed by aspiration and each bottle was washed with 20 ml PBS.
- Cell Seeding 5.0E+06 P9 umbilical-derived cells (# 050604B) were thawed from a single cryogenic vial and washed to remove DMSO. Cells (2.12E+06) were seeded into a single 850 cm sq roller bottle pre-filled with 300 ml media and pre-gassed for 1 minute with compressed air containing 5% CO 2 , 95% atmospheric gas.
- Cells used for characterization experiments were umbilicus-derived cells at passage 6 (050604B P6)
- Growth Medium Dulbecco's Modified Eagle Medium (DMEM) -low glucose, 15% Fetal Bovine Serum, Penicillin-Streptomycin, 2-Mercaptoethanol was used as the growth medium.
- DMEM Dulbecco's Modified Eagle Medium
- Bottles 850 cm sq bottles (e.g. Coming catalog number 430851)
- Gelatin Coating Twenty (20) ml of 2% gelatin solution was added to each 850 cm sq bottle. The bottles were placed on the roller system for 20 minutes. The gelatin solution was removed by aspiration and each bottle was washed with 20 ml PBS.
- Antibody Staining for Flow Cytometry Analysis Cells were and re-suspended in 3% (v/v) FBS in PBS at a cell concentration of 1x107 per milliliter. Antibody is added as per manufacture's specifications and incubated with cells in the dark for 30 minutes at 4 0 C. After incubation, cells were washed with PBS and centrifuged to remove unbound antibody. Cells were re-suspended in 500 microliter PBS and analyzed by flow cytometry.
- Flow Cytometry Analysis Flow cytometry analysis was performed with a FACScalibur (Becton Dickinson San Jose, CA) instrument.
- Antibodies The following antibodies were used:
- CD13 BD Pharmingen (San Diego, CA) 555394
- CD34 BD Pharmingen (San Diego, CA) 555821
- CD44 BD Pharmingen (San Diego, CA) 555478
- CD45RA BD Pharmingen (San Diego, CA) 555489
- CD73 BD Pharmingen (San Diego, CA) 550257
- CD90 BD Pharmingen (San Diego, CA) 555596
- HLA-A, B, C BD Pharmingen (San Diego, CA) 555553
- Real-time PCR PCR was performed on cDNA samples using Assays-on- DemandTM gene expression products: oxidized LDL receptor (Hs00234028), renin (HsOO 166915), reticulon (HsOO382515) CXC ligand 3 (HsOOl 71061), GCP-2 (Hs00605742) IL- 8 (HsOO 174103) and GAPDH (Applied Biosystems, Foster City, CA) were mixed with cDNA and TaqMan Universal PCR master mix according to the manufacturer's instructions (Applied Biosystems, Foster City, CA) using a 7000 sequence detection system with ABI prism 7000 SDS software (Applied Biosystems, Foster City, CA). Thermal cycle conditions were initially 50 0 C for 2 min and 95°C for 10 min followed by 40 cycles of 95°C for 15 sec and 60 0 C for 1 min.
- CD 10 ( + ) ( + ) CD 13 ( + ) ( + ) CD 31 ( - ) ( - ) CD 34 ( - ) ( - ) CD 44 ( + ) ( + ) CD 45 ( - ) ( - ) CD 73 ( + ) ( + ) CD 90 ( + ) ( + )
- Table 7 Comparison of CT values for genes expressed by cells (Umb 050604B) expanded in static plastic with those grown TC flasks in the optimized roller bottle conditions.
- DMEM Dulbecco's Modified Eagle Medium
- Bottles Corning 850 cm sq bottles (catalog number 430851), CellBind Corning 850 cm sq bottles (catalog number 3907)
- Gelatin Coating 20 ml of 2% gelatin solution is added to Corning 850 cm sq bottles (catalog number 430851) and placed on the roller system for 20 minutes. The gelatin solution is removed by aspiration and washed with 20 ml PBS. CellBind Corning 850 cm sq bottles are not coated.
- Table 8 Actual Cell Yield per Passage for Cells Grown in Gelatin-coated Roller Bottles versus Bottles with CellBind.
- Umb050604B Optimal Roller Bottle- CellBind Passage Seede Yield Date Expansion Doubling Time Time Hours/ Harvest (days) (hrs) doubling Density
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008547732A JP5179376B2 (en) | 2005-12-19 | 2006-12-19 | In vitro growth of postpartum-extracted cells in roller bottles |
EP06840316A EP1976975B1 (en) | 2005-12-19 | 2006-12-19 | In vitro expansion of postpartum derived cells in roller bottles |
CN200680053021.3A CN101410511B (en) | 2005-12-19 | 2006-12-19 | In vitro expansion of postpartum derived cells in roller bottles |
AU2006327073A AU2006327073B2 (en) | 2005-12-19 | 2006-12-19 | In vitro expansion of postpartum derived cells in roller bottles |
ES06840316T ES2391034T3 (en) | 2005-12-19 | 2006-12-19 | In vitro expansion of postpartum derived cells in rotary bottles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75155005P | 2005-12-19 | 2005-12-19 | |
US60/751,550 | 2005-12-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007073552A1 true WO2007073552A1 (en) | 2007-06-28 |
Family
ID=37882293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/062315 WO2007073552A1 (en) | 2005-12-19 | 2006-12-19 | In vitro expansion of postpartum derived cells in roller bottles |
Country Status (7)
Country | Link |
---|---|
US (1) | US8741638B2 (en) |
EP (1) | EP1976975B1 (en) |
JP (1) | JP5179376B2 (en) |
CN (1) | CN101410511B (en) |
AU (1) | AU2006327073B2 (en) |
ES (1) | ES2391034T3 (en) |
WO (1) | WO2007073552A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691217B2 (en) | 2005-12-29 | 2014-04-08 | Anthrogenesis Corporation | Placental stem cell populations |
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
US8926964B2 (en) | 2010-07-13 | 2015-01-06 | Anthrogenesis Corporation | Methods of generating natural killer cells |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
US9102915B2 (en) | 2006-11-13 | 2015-08-11 | DePuy Synthes Products, Inc. | In vitro expansion of postpartum-derived cells using microcarriers |
US9121007B2 (en) | 2010-01-26 | 2015-09-01 | Anthrogenesis Corporatin | Treatment of bone-related cancers using placental stem cells |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
US9175261B2 (en) | 2005-12-16 | 2015-11-03 | DePuy Synthes Products, Inc. | Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
US9216200B2 (en) | 2007-09-28 | 2015-12-22 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
US9254302B2 (en) | 2010-04-07 | 2016-02-09 | Anthrogenesis Corporation | Angiogenesis using placental stem cells |
US9498501B2 (en) | 2003-06-27 | 2016-11-22 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
US9943552B2 (en) | 2009-03-26 | 2018-04-17 | DePuy Synthes Products, Inc. | hUTC as therapy for Alzheimer's disease |
US10104880B2 (en) | 2008-08-20 | 2018-10-23 | Celularity, Inc. | Cell composition and methods of making the same |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
US10557116B2 (en) | 2008-12-19 | 2020-02-11 | DePuy Synthes Products, Inc. | Treatment of lung and pulmonary diseases and disorders |
US11891646B2 (en) | 2010-01-15 | 2024-02-06 | Massachusetts Institute Of Technology | Bioprocess and microbe engineering for total carbon utilization in biofuel production |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
US8491883B2 (en) * | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
US7875272B2 (en) * | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
WO2006101548A2 (en) * | 2004-12-21 | 2006-09-28 | Ethicon, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
WO2006083394A2 (en) * | 2004-12-21 | 2006-08-10 | Ethicon, Inc. | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
US20060153815A1 (en) * | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
CA2592435C (en) | 2004-12-23 | 2017-03-28 | Ethicon, Incorporated | Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells |
PL1831356T3 (en) * | 2004-12-23 | 2017-07-31 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
ES2452595T3 (en) * | 2005-10-13 | 2014-04-02 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
WO2007073552A1 (en) | 2005-12-19 | 2007-06-28 | Ethicon, Inc. | In vitro expansion of postpartum derived cells in roller bottles |
WO2007076522A2 (en) * | 2005-12-28 | 2007-07-05 | Ethicon, Incorporated | Treatment of peripheral vascular disease using postpartum-derived cells |
WO2008045498A1 (en) | 2006-10-12 | 2008-04-17 | Ethicon, Inc. | Kidney-derived cells and methods of use in tissue repair and regeneration |
DK2084268T3 (en) | 2006-10-23 | 2019-01-21 | Celularity Inc | METHODS AND COMPOSITIONS FOR TREATING BONE JOIN DEFECTS WITH PLACENTACLE POPULATIONS |
DK2120977T3 (en) | 2007-02-12 | 2013-08-12 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
US8034329B2 (en) * | 2007-10-05 | 2011-10-11 | Advanced Technologies And Regenerative Medicine, Llc | Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells |
US8236538B2 (en) | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
KR101903049B1 (en) | 2008-08-20 | 2018-11-07 | 안트로제네시스 코포레이션 | Treatment of stroke using isolated placental cells |
KR20110050688A (en) | 2008-08-22 | 2011-05-16 | 안트로제네시스 코포레이션 | Methods and compositions for treatment of bone defects with placental cell populations |
US8906306B2 (en) * | 2009-04-09 | 2014-12-09 | Roche Molecular Systems, Inc. | Fluid transfer control for real-time PCR |
WO2011127113A1 (en) | 2010-04-08 | 2011-10-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
JP5853512B2 (en) * | 2011-09-08 | 2016-02-09 | 大日本印刷株式会社 | Cell culture container and manufacturing method thereof |
US20140170748A1 (en) | 2012-12-14 | 2014-06-19 | DePuy Synthes Products, LLC | Nutrient Enriched Media for hUTC Growth |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005001078A2 (en) * | 2003-06-27 | 2005-01-06 | Ethicon, Incorporated | Regeneration and repair of neural tissue using postpartum-derived cells |
US20060223177A1 (en) * | 2003-06-27 | 2006-10-05 | Ethicon Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
Family Cites Families (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US5266476A (en) * | 1985-06-18 | 1993-11-30 | Yeda Research & Development Co., Ltd. | Fibrous matrix for in vitro cell cultivation |
US5902741A (en) | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
US4963489A (en) | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US5266480A (en) | 1986-04-18 | 1993-11-30 | Advanced Tissue Sciences, Inc. | Three-dimensional skin culture system |
US5863531A (en) | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
US5460939A (en) | 1986-04-18 | 1995-10-24 | Advanced Tissue Sciences, Inc. | Temporary living skin replacement |
CA1322262C (en) | 1987-06-26 | 1993-09-21 | Yoshito Ikada | Artificial skin |
JPH0191775A (en) * | 1987-10-01 | 1989-04-11 | Snow Brand Milk Prod Co Ltd | Culture of adhesive animal cell |
NZ226750A (en) | 1987-10-29 | 1990-09-26 | Amrad Corp Ltd | Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene |
US5004681B1 (en) | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US5192553A (en) | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
GB8803697D0 (en) | 1988-02-17 | 1988-03-16 | Deltanine Research Ltd | Clinical developments using amniotic membrane cells |
US20030032178A1 (en) | 1988-08-04 | 2003-02-13 | Williams Robert Lindsay | In vitro propagation of embryonic stem cells |
US5437994A (en) | 1989-06-15 | 1995-08-01 | Regents Of The University Of Michigan | Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US5840580A (en) | 1990-05-01 | 1998-11-24 | Becton Dickinson And Company | Phenotypic characterization of the hematopoietic stem cell |
US5342761A (en) | 1990-10-01 | 1994-08-30 | Research Development Foundation | Oncofetal gene, gene product and uses therefor |
US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5286632A (en) | 1991-01-09 | 1994-02-15 | Jones Douglas H | Method for in vivo recombination and mutagenesis |
US6399369B1 (en) | 1991-07-08 | 2002-06-04 | Neurospheres Holdings Ltd. | Multipotent neural stem cell cDNA libraries |
WO1993003139A1 (en) | 1991-08-08 | 1993-02-18 | Kao Corporation | Cell culture support, production thereof, and production of cell cluster using same |
WO1994000484A1 (en) | 1992-06-22 | 1994-01-06 | Young Henry E | Scar inhibitory factor and use thereof |
US5320962A (en) | 1992-07-22 | 1994-06-14 | Duke University | DNA encoding the human A1 adenosine receptor |
US5589376A (en) | 1992-07-27 | 1996-12-31 | California Institute Of Technology | Mammalian neural crest stem cells |
ATE250138T1 (en) | 1992-10-29 | 2003-10-15 | Univ Australian | ANGIOGENESIS-INHIBITING ANTIBODIES |
US5670483A (en) | 1992-12-28 | 1997-09-23 | Massachusetts Insititute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
IL110589A0 (en) | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
US6686198B1 (en) | 1993-10-14 | 2004-02-03 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
US6432711B1 (en) | 1993-11-03 | 2002-08-13 | Diacrin, Inc. | Embryonic stem cells capable of differentiating into desired cell lines |
US5456835A (en) | 1993-11-08 | 1995-10-10 | Hemasure, Inc. | Device and process for removing free hemoglobin from blood |
US5834308A (en) | 1994-04-28 | 1998-11-10 | University Of Florida Research Foundation, Inc. | In vitro growth of functional islets of Langerhans |
US6001647A (en) | 1994-04-28 | 1999-12-14 | Ixion Biotechnology, Inc. | In vitro growth of functional islets of Langerhans and in vivo uses thereof |
US6703017B1 (en) | 1994-04-28 | 2004-03-09 | Ixion Biotechnology, Inc. | Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
US5906934A (en) | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US6200606B1 (en) | 1996-01-16 | 2001-03-13 | Depuy Orthopaedics, Inc. | Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration |
US5842477A (en) | 1996-02-21 | 1998-12-01 | Advanced Tissue Sciences, Inc. | Method for repairing cartilage |
CA2248549A1 (en) | 1996-03-15 | 1997-09-18 | Munin Corporation | Extracellular matrix signalling molecules |
US5730933A (en) | 1996-04-16 | 1998-03-24 | Depuy Orthopaedics, Inc. | Radiation sterilization of biologically active compounds |
JP2000508922A (en) | 1996-04-26 | 2000-07-18 | ケース ウエスターン リザーブ ユニバーシティ | Skin regeneration using mesenchymal stem cells |
US6358737B1 (en) | 1996-07-31 | 2002-03-19 | Board Of Regents, The University Of Texas System | Osteocyte cell lines |
US6787355B1 (en) | 1996-08-26 | 2004-09-07 | Mcgill University | Multipotent neural stem cells from peripheral tissues and uses thereof |
US5919702A (en) | 1996-10-23 | 1999-07-06 | Advanced Tissue Science, Inc. | Production of cartilage tissue using cells isolated from Wharton's jelly |
CN100529063C (en) | 1997-12-02 | 2009-08-19 | 泽恩比奥公司 | Differentiation of adipose stromal cells into osteobalsts and uses thereof |
US6059968A (en) | 1998-01-20 | 2000-05-09 | Baxter International Inc. | Systems for processing and storing placenta/umbilical cord blood |
US6291240B1 (en) | 1998-01-29 | 2001-09-18 | Advanced Tissue Sciences, Inc. | Cells or tissues with increased protein factors and methods of making and using same |
WO1999046366A1 (en) | 1998-03-13 | 1999-09-16 | Osiris Therapeutics, Inc. | Uses for humane non-autologous mesenchymal stem cells |
EP1076563B1 (en) | 1998-03-16 | 2005-05-11 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
US6171610B1 (en) | 1998-04-24 | 2001-01-09 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
AU3888699A (en) | 1998-05-07 | 1999-11-23 | University Of South Florida | Bone marrow cells as a source of neurons for brain and spinal cord repair |
ATE368731T1 (en) | 1998-05-29 | 2007-08-15 | Osiris Therapeutics Inc | HUMAN CD45+ AND/OR FIBROBLASTS+ MESENCHYMAL STEM CELLS |
US6323188B1 (en) | 1998-07-01 | 2001-11-27 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases, heart attack, and stroke, primary and subsequent, with help of aspirin and certain vitamins |
US20040037818A1 (en) | 1998-07-30 | 2004-02-26 | Brand Stephen J. | Treatment for diabetes |
US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
US6284245B1 (en) | 1998-08-25 | 2001-09-04 | Diacrin, Inc. | Neural retinal cells and retinal pigment epithelium cells and their use in treatment of retinal disorders |
MXPA01007810A (en) | 1999-02-04 | 2003-06-04 | Univ Mcgill | Platform for the differentiation of cells. |
AU780794B2 (en) | 1999-02-10 | 2005-04-14 | Es Cell International Pte Ltd | Pancreatic progenitor cells, methods and uses related thereto |
US20030007954A1 (en) | 1999-04-12 | 2003-01-09 | Gail K. Naughton | Methods for using a three-dimensional stromal tissue to promote angiogenesis |
DE60026983T2 (en) | 1999-04-16 | 2007-01-25 | William Marsh Rice University, Houston | FUNCTIONALIZED POLYPROPYLENE FUMARATE AND POLYPROPYLENE FUMARATE COETHYLENE GLYCOL |
US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
US6287340B1 (en) | 1999-05-14 | 2001-09-11 | Trustees Of Tufts College | Bioengineered anterior cruciate ligament |
US6355699B1 (en) | 1999-06-30 | 2002-03-12 | Ethicon, Inc. | Process for manufacturing biomedical foams |
US6333029B1 (en) | 1999-06-30 | 2001-12-25 | Ethicon, Inc. | Porous tissue scaffoldings for the repair of regeneration of tissue |
US6429013B1 (en) | 1999-08-19 | 2002-08-06 | Artecel Science, Inc. | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair |
US6555374B1 (en) | 1999-08-19 | 2003-04-29 | Artecel Sciences, Inc. | Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US20030129745A1 (en) | 1999-10-28 | 2003-07-10 | Robl James M. | Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
US20020164307A1 (en) | 1999-12-06 | 2002-11-07 | Habener Joel F. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
CN100475953C (en) | 1999-12-06 | 2009-04-08 | 通用医疗公司 | Pancreatic stem cells |
US20030082155A1 (en) | 1999-12-06 | 2003-05-01 | Habener Joel F. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
US7785882B2 (en) | 2000-01-18 | 2010-08-31 | Cornell Research Foundation, Inc. | Neuronal progenitor cells from hippocampal tissue and a method for isolating and purifying them |
US7544509B2 (en) | 2000-01-24 | 2009-06-09 | Mcgill University | Method for preparing stem cell preparations |
US6610535B1 (en) | 2000-02-10 | 2003-08-26 | Es Cell International Pte Ltd. | Progenitor cells and methods and uses related thereto |
AU3499801A (en) | 2000-02-11 | 2001-08-20 | Schepens Eye Res Inst | Isolation and transplantation of retinal stem cells |
WO2001059072A1 (en) | 2000-02-11 | 2001-08-16 | Philadelphia Health And Education Corporation | Differentiation of bone marrow cells into neuronal cells and uses therefor |
EP1263930A4 (en) | 2000-03-09 | 2004-07-21 | Saneron Ccel Therapeutics Inc | Human cord blood as a source of neural tissue for repair of the brain and spinal cord |
US6436704B1 (en) | 2000-04-10 | 2002-08-20 | Raven Biotechnologies, Inc. | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof |
US6673606B1 (en) | 2000-04-12 | 2004-01-06 | The Children's Hospital Of Philadelphia | Therapeutic uses for mesenchymal stromal cells |
EP1318833A2 (en) | 2000-05-12 | 2003-06-18 | The University of Utah Research Foundation | Compositions and methods for cell dedifferentiation and tissue regeneration |
US8273570B2 (en) | 2000-05-16 | 2012-09-25 | Riken | Process of inducing differentiation of embryonic cell to cell expressing neural surface marker using OP9 or PA6 cells |
US7049072B2 (en) | 2000-06-05 | 2006-05-23 | University Of South Florida | Gene expression analysis of pluri-differentiated mesenchymal progenitor cells and methods for diagnosing a leukemic disease state |
US6759039B2 (en) | 2000-06-30 | 2004-07-06 | Amcyte, Inc. | Culturing pancreatic stem cells having a specified, intermediate stage of development |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
WO2002026941A2 (en) | 2000-09-29 | 2002-04-04 | Kooy Derek V D | Primitive neural stem cells and method for differentiation of stem cells to neural cells |
AU2002230669A1 (en) | 2000-11-06 | 2002-05-15 | The Salk Institute For Biological Studies | Postmortem stem cells |
IL156234A0 (en) | 2000-11-30 | 2004-01-04 | Stemron Inc | Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
US20030032179A1 (en) | 2000-12-06 | 2003-02-13 | Hariri Robert J. | Post-partum mammalian placenta, its use and placental stem cells therefrom |
AU2002220209B2 (en) | 2000-12-06 | 2006-05-25 | Robert J. Hariri | Method of collecting placental stem cells |
US6599323B2 (en) | 2000-12-21 | 2003-07-29 | Ethicon, Inc. | Reinforced tissue implants and methods of manufacture and use |
CA2365376C (en) | 2000-12-21 | 2006-03-28 | Ethicon, Inc. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
US7449180B2 (en) | 2001-02-06 | 2008-11-11 | John Kisiday | Macroscopic scaffold containing amphiphilic peptides encapsulating cells |
KR101012952B1 (en) | 2001-02-14 | 2011-02-08 | 안트로제네시스 코포레이션 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
CA2442177A1 (en) | 2001-03-29 | 2002-10-10 | Ixion Biotechnology, Inc. | Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway |
US20030211605A1 (en) | 2001-05-01 | 2003-11-13 | Lee Sang-Hun | Derivation of midbrain dopaminergic neurons from embryonic stem cells |
US20030022369A1 (en) | 2001-05-18 | 2003-01-30 | Helen Fillmore | Differentiation of specialized dermal and epidermal cells into neuronal cells |
JP2005515753A (en) | 2001-05-25 | 2005-06-02 | サイセラ,インコーポレイテッド | Stem cell differentiation |
EP1423504B1 (en) | 2001-08-08 | 2009-09-23 | Levesque Biosciences, Inc. | Compositions and methods for isolation, propagation, and differentiation of non-embryonic human stem cells and uses thereof |
US20030211603A1 (en) | 2001-08-14 | 2003-11-13 | Earp David J. | Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells |
WO2003018767A2 (en) | 2001-08-27 | 2003-03-06 | Advanced Cell Technology, Inc. | Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
US20030104997A1 (en) | 2001-09-05 | 2003-06-05 | Black Ira B. | Multi-lineage directed induction of bone marrow stromal cell differentiation |
EP1444345A4 (en) | 2001-10-18 | 2004-12-08 | Ixion Biotechnology Inc | Conversion of liver stem and progenitor cells to pancreatic functional cells |
US7129034B2 (en) | 2001-10-25 | 2006-10-31 | Cedars-Sinai Medical Center | Differentiation of whole bone marrow |
JP2005533480A (en) | 2001-11-09 | 2005-11-10 | アーテセル・サイエンシズ・インコーポレーテツド | Pancreatic endocrine differentiation of adipose tissue-derived stromal cells and use thereof |
JP3728750B2 (en) | 2001-11-22 | 2005-12-21 | ニプロ株式会社 | Cultured skin and method for producing the same |
US20030109036A1 (en) | 2001-12-06 | 2003-06-12 | The Regents Of The University Of California | Method for differentiating islet precursor cells into beta cells |
KR101008868B1 (en) | 2001-12-07 | 2011-01-17 | 제론 코포레이션 | Islet cells from human embryonic stem cells |
JP3934539B2 (en) | 2001-12-12 | 2007-06-20 | 独立行政法人科学技術振興機構 | Adult or postnatal tissue progenitor cells derived from placenta |
US20030113910A1 (en) | 2001-12-18 | 2003-06-19 | Mike Levanduski | Pluripotent stem cells derived without the use of embryos or fetal tissue |
US7101546B2 (en) | 2001-12-21 | 2006-09-05 | Amcyte, Inc. | In situ maturation of cultured pancreatic stem cells having a specified, intermediate stage of development |
WO2003055989A2 (en) | 2001-12-21 | 2003-07-10 | Mount Sinai Hospital | Cellular compositions and methods of making and using them |
US7357895B2 (en) | 2002-01-04 | 2008-04-15 | Osteotech, Inc. | Method for sterilizing bioactive materials |
JP2005514926A (en) | 2002-01-14 | 2005-05-26 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | Novel mammalian multipotent stem cells and compositions, methods for their preparation and administration |
US20030162290A1 (en) | 2002-01-25 | 2003-08-28 | Kazutomo Inoue | Method for inducing differentiation of embryonic stem cells into functioning cells |
WO2003070189A2 (en) | 2002-02-15 | 2003-08-28 | Cornell Research Foundation, Inc. | Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein |
US7736892B2 (en) | 2002-02-25 | 2010-06-15 | Kansas State University Research Foundation | Cultures, products and methods using umbilical cord matrix cells |
US20030161818A1 (en) | 2002-02-25 | 2003-08-28 | Kansas State University Research Foundation | Cultures, products and methods using stem cells |
US7150990B2 (en) | 2002-03-06 | 2006-12-19 | Reprocell, Inc. | Self-renewing pluripotent hepatic stem cells |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
JP4136434B2 (en) | 2002-04-17 | 2008-08-20 | 進 清野 | Induction of insulin-producing cells |
EP1497435A4 (en) | 2002-04-19 | 2005-07-27 | Univ Pittsburgh | Placental derived stem cells and uses thereof |
US20040029269A1 (en) | 2002-05-07 | 2004-02-12 | Goldman Steven A | Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells |
US20040014662A1 (en) | 2002-05-08 | 2004-01-22 | Per Lindquist | Modulation of neural stem cells and neural progenitor cells |
WO2003104423A2 (en) | 2002-06-11 | 2003-12-18 | Roy Ogle | Meningeal-derived stem cells |
US7285415B2 (en) | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
US7390659B2 (en) | 2002-07-16 | 2008-06-24 | The Trustees Of Columbia University In The City Of New York | Methods for inducing differentiation of embryonic stem cells and uses thereof |
AU2003242976A1 (en) | 2002-07-16 | 2004-02-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of implanting mesenchymal stem cells for tissue repair and formation |
WO2004020601A2 (en) | 2002-08-28 | 2004-03-11 | University Of Florida | Neurogenesis from hepatic stem cells |
US9969977B2 (en) | 2002-09-20 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
JP4790592B2 (en) | 2003-02-11 | 2011-10-12 | ダビース,ジヨン・イー | Progenitor cells from Wharton's jelly of human umbilical cord |
US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
US8039258B2 (en) | 2004-09-28 | 2011-10-18 | Ethicon, Inc. | Tissue-engineering scaffolds containing self-assembled-peptide hydrogels |
US20060153815A1 (en) | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
WO2006101548A2 (en) | 2004-12-21 | 2006-09-28 | Ethicon, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
WO2006083394A2 (en) | 2004-12-21 | 2006-08-10 | Ethicon, Inc. | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
CA2592435C (en) | 2004-12-23 | 2017-03-28 | Ethicon, Incorporated | Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells |
PL1971681T3 (en) | 2005-12-16 | 2018-01-31 | Depuy Synthes Products Inc | Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
WO2007073552A1 (en) | 2005-12-19 | 2007-06-28 | Ethicon, Inc. | In vitro expansion of postpartum derived cells in roller bottles |
WO2007076522A2 (en) | 2005-12-28 | 2007-07-05 | Ethicon, Incorporated | Treatment of peripheral vascular disease using postpartum-derived cells |
KR20210122908A (en) | 2005-12-29 | 2021-10-12 | 안트로제네시스 코포레이션 | Placental stem cell populations |
WO2008045498A1 (en) | 2006-10-12 | 2008-04-17 | Ethicon, Inc. | Kidney-derived cells and methods of use in tissue repair and regeneration |
ES2524443T3 (en) | 2006-11-13 | 2014-12-09 | DePuy Synthes Products, LLC | In vitro expansion of postpartum cells using microcarriers |
-
2006
- 2006-12-19 WO PCT/US2006/062315 patent/WO2007073552A1/en active Application Filing
- 2006-12-19 CN CN200680053021.3A patent/CN101410511B/en not_active Expired - Fee Related
- 2006-12-19 JP JP2008547732A patent/JP5179376B2/en not_active Expired - Fee Related
- 2006-12-19 EP EP06840316A patent/EP1976975B1/en not_active Not-in-force
- 2006-12-19 ES ES06840316T patent/ES2391034T3/en active Active
- 2006-12-19 AU AU2006327073A patent/AU2006327073B2/en not_active Ceased
- 2006-12-19 US US11/612,872 patent/US8741638B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005001078A2 (en) * | 2003-06-27 | 2005-01-06 | Ethicon, Incorporated | Regeneration and repair of neural tissue using postpartum-derived cells |
US20050019865A1 (en) * | 2003-06-27 | 2005-01-27 | Kihm Anthony J. | Cartilage and bone repair and regeneration using postpartum-derived cells |
US20060223177A1 (en) * | 2003-06-27 | 2006-10-05 | Ethicon Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
Non-Patent Citations (2)
Title |
---|
MELERO-MARTIN JUAN M ET AL: "Optimal in-vitro expansion of chondroprogenitor cells in monolayer culture", BIOTECHNOLOGY AND BIOENGINEERING, vol. 93, no. 3, February 2006 (2006-02-01), pages 519 - 533, XP002427626, ISSN: 0006-3592 * |
ULLOA-MONTOYA ET AL: "Culture systems for pluripotent stem cells", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, ELSEVIER, AMSTERDAM,, NL, vol. 100, no. 1, 2005, pages 12 - 27, XP005046474, ISSN: 1389-1723 * |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
US11191789B2 (en) | 2003-06-27 | 2021-12-07 | DePuy Synthes Products, Inc. | Cartilage and bone repair and regeneration using postpartum-derived cells |
US11179422B2 (en) | 2003-06-27 | 2021-11-23 | DePuy Synthes Products, Inc. | Method of differentiating umbilical cord tissue into a chondrogenic phenotype |
US11000554B2 (en) | 2003-06-27 | 2021-05-11 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US10758576B2 (en) | 2003-06-27 | 2020-09-01 | DePuy Synthes Products, Inc. | Soft tissue repair and regeneration using postpartum-derived cells and cell products |
US10744164B2 (en) | 2003-06-27 | 2020-08-18 | DePuy Synthes Products, Inc. | Repair and regeneration of ocular tissue using postpartum-derived cells |
US10500234B2 (en) | 2003-06-27 | 2019-12-10 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US10383898B2 (en) | 2003-06-27 | 2019-08-20 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US10220059B2 (en) | 2003-06-27 | 2019-03-05 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US10195233B2 (en) | 2003-06-27 | 2019-02-05 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US9234172B2 (en) | 2003-06-27 | 2016-01-12 | DePuy Synthes Products, Inc. | Repair and regeneration of ocular tissue using postpartum-derived cells |
US10039793B2 (en) | 2003-06-27 | 2018-08-07 | DePuy Synthes Products, Inc. | Soft tissue repair and regeneration using postpartum-derived cells and cell products |
US9717763B2 (en) | 2003-06-27 | 2017-08-01 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US9498501B2 (en) | 2003-06-27 | 2016-11-22 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US9504719B2 (en) | 2003-06-27 | 2016-11-29 | DePuy Synthes Products, Inc. | Soft tissue repair and regeneration using postpartum-derived cells and cell products |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
US9579351B2 (en) | 2003-06-27 | 2017-02-28 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US9175261B2 (en) | 2005-12-16 | 2015-11-03 | DePuy Synthes Products, Inc. | Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
US9585918B2 (en) | 2005-12-28 | 2017-03-07 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
US9078898B2 (en) | 2005-12-29 | 2015-07-14 | Anthrogenesis Corporation | Placental stem cell populations |
US10383897B2 (en) | 2005-12-29 | 2019-08-20 | Celularity, Inc. | Placental stem cell populations |
US8691217B2 (en) | 2005-12-29 | 2014-04-08 | Anthrogenesis Corporation | Placental stem cell populations |
US9102915B2 (en) | 2006-11-13 | 2015-08-11 | DePuy Synthes Products, Inc. | In vitro expansion of postpartum-derived cells using microcarriers |
US9216200B2 (en) | 2007-09-28 | 2015-12-22 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
US10104880B2 (en) | 2008-08-20 | 2018-10-23 | Celularity, Inc. | Cell composition and methods of making the same |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
US10557116B2 (en) | 2008-12-19 | 2020-02-11 | DePuy Synthes Products, Inc. | Treatment of lung and pulmonary diseases and disorders |
US9943552B2 (en) | 2009-03-26 | 2018-04-17 | DePuy Synthes Products, Inc. | hUTC as therapy for Alzheimer's disease |
US11891646B2 (en) | 2010-01-15 | 2024-02-06 | Massachusetts Institute Of Technology | Bioprocess and microbe engineering for total carbon utilization in biofuel production |
US9121007B2 (en) | 2010-01-26 | 2015-09-01 | Anthrogenesis Corporatin | Treatment of bone-related cancers using placental stem cells |
US9254302B2 (en) | 2010-04-07 | 2016-02-09 | Anthrogenesis Corporation | Angiogenesis using placental stem cells |
US9464274B2 (en) | 2010-07-13 | 2016-10-11 | Anthrogenesis Corporation | Methods of generating natural killer cells |
US8926964B2 (en) | 2010-07-13 | 2015-01-06 | Anthrogenesis Corporation | Methods of generating natural killer cells |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
US11090339B2 (en) | 2011-06-01 | 2021-08-17 | Celularity Inc. | Treatment of pain using placental stem cells |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
Also Published As
Publication number | Publication date |
---|---|
CN101410511A (en) | 2009-04-15 |
JP5179376B2 (en) | 2013-04-10 |
EP1976975B1 (en) | 2012-08-01 |
AU2006327073A1 (en) | 2007-06-28 |
CN101410511B (en) | 2015-02-25 |
AU2006327073B2 (en) | 2012-08-30 |
JP2009519728A (en) | 2009-05-21 |
US20070141700A1 (en) | 2007-06-21 |
EP1976975A1 (en) | 2008-10-08 |
US8741638B2 (en) | 2014-06-03 |
ES2391034T3 (en) | 2012-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8741638B2 (en) | In vitro expansion of postpartum-derived cells in roller bottles | |
Nienow et al. | Agitation conditions for the culture and detachment of hMSCs from microcarriers in multiple bioreactor platforms | |
Gilbertson et al. | Scaled‐up production of mammalian neural precursor cell aggregates in computer‐controlled suspension bioreactors | |
EP2089511B1 (en) | In vitro expansion of postpartum-derived cells using microcarriers | |
KR102151588B1 (en) | NUTRIENT ENRICHED MEDIA FOR hUTC GROWTH | |
JP2010508851A5 (en) | ||
Das et al. | Preparing for cell culture scale-out: establishing parity of bioreactor-and flask-expanded mesenchymal stromal cell cultures | |
EP3933032A1 (en) | Three-dimensional culture method for large-scale preparation of stem cells | |
Carmelo et al. | Scalable ex vivo expansion of human mesenchymal stem/stromal cells in microcarrier-based stirred culture systems | |
US20220395537A1 (en) | Methods of stem cell culture for obtaining products, and implementations thereof | |
CN101821383A (en) | A kind of primary mesenchymal stem cells and application thereof that is used for substratum, method and the acquisition of the external mass-producing cultivation of human adult primary mesenchymal stem cells | |
JPS629318B2 (en) | ||
CN110872574B (en) | Efficient and reliable hESC-MSC preparation method | |
Yu et al. | Ex vitro expansion of human placenta-derived mesenchymal stem cells in stirred bioreactor | |
Kibschull | Differentiating mouse embryonic stem cells into embryoid bodies in AggreWell plates | |
CN111690686B (en) | Application of miRNA high expression in promoting in-vitro proliferation and osteogenic differentiation of umbilical cord mesenchymal stem cells | |
US20190002821A1 (en) | Methods and compositions for detaching adherent cells | |
Rourou et al. | Development of an in situ detachment protocol of Vero cells grown on Cytodex1 microcarriers under animal component-free conditions in stirred bioreactor | |
CN114214285A (en) | Application of lncRNA in inhibiting aging of umbilical cord mesenchymal stem cells through high expression | |
CN109837241A (en) | The separation of fat stem cell and cultural method | |
CN110079497A (en) | Method for separating and culturing adipose-derived stem cells | |
Müthing et al. | Microcarrier cultivation of bovine aortic endothelial cells in spinner vessels and a membrane stirred bioreactor | |
CN111206015B (en) | Three-dimensional dynamic culture method for amplifying spermatogonial stem cells in vitro by using FACT III microcarriers | |
CN117757739A (en) | Method for establishing mesenchymal stem cell seed bank by mixing tissues from different donors | |
CN116410922A (en) | Method for separating and differentiating animal fat source mesenchymal precursor cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2356/KOLNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008547732 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006327073 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006840316 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006327073 Country of ref document: AU Date of ref document: 20061219 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680053021.3 Country of ref document: CN |